Table 1 Patient and treatment characteristics
RMS patients ( n =30) | ||
|---|---|---|
Number | Fraction | |
Age at diagnosis (years) | ||
0–9 | 8 | 0.27 |
10–19 | 19 | 0.63 |
20–29 | 3 | 0.10 |
Gender | ||
Male | 17 | 0.57 |
Female | 13 | 0.43 |
Date of diagnosis | ||
<2000 | 4 | 0.13 |
⩾2000 | 26 | 0.87 |
Date of last allo-SCT | ||
<2000 | 1 | 0.03 |
⩾2000 | 29 | 0.97 |
RMS subtype | ||
Alveolar | 23 | 0.77 |
Embryonal | 3 | 0.10 |
Unknown | 4 | 0.13 |
First-line local treatment modality | ||
Surgery only | 5 | 0.17 |
Irradiation only | 9 | 0.30 |
Surgery+Irradiation | 9 | 0.30 |
None | 5 | 0.17 |
Unknown | 2 | 0.07 |
Stage at diagnosis | ||
Stage II at Diagnosis | 1 | 0.03 |
Stage III at Diagnosis | 3 | 0.10 |
Stage IV at Diagnosis | 23 | 0.77 |
Unknown | 3 | 0.10 |
Status at allo-SCT | ||
CR | 24 | 0.80 |
Residual disease | 6 | 0.20 |
Previous graft | ||
No previous graft | 20 | 0.67 |
Allogeneic graft once | 1 | 0.03 |
Autologous graft(s) | 9 | 0.30 |
Transplant conditioning regimen | ||
RIC | 20 | 0.67 |
HDC | 10 | 0.33 |
Total body irradiation | ||
Yes (all 2 Gy) | 4 | 0.13 |
No | 26 | 0.87 |
Graft source for allo-SCT | ||
BM | 16 | 0.53 |
PB | 10 | 0.33 |
CB | 4 | 0.13 |
Donor HLA match | ||
Matched related | 17 | 0.57 |
Matched unrelated | 6 | 0.20 |
Mismatcheda | 7 | 0.23 |
DLI after allo-SCT | ||
Yes | 3 | 0.10 |
No | 26 | 0.87 |
Unknown | 1 | 0.03 |
